OCDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ortho Clinical Diagnostics Holdings's Enterprise Value is $6,163 Mil. Ortho Clinical Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 was $130 Mil. Therefore, Ortho Clinical Diagnostics Holdings's EV-to-EBIT ratio for today is 47.30.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Ortho Clinical Diagnostics Holdings's Enterprise Value is $6,163 Mil. Ortho Clinical Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 was $455 Mil. Therefore, Ortho Clinical Diagnostics Holdings's EV-to-EBITDA ratio for today is 13.54.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Ortho Clinical Diagnostics Holdings's Enterprise Value is $6,163 Mil. Ortho Clinical Diagnostics Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 was $2,036 Mil. Therefore, Ortho Clinical Diagnostics Holdings's EV-to-Revenue ratio for today is 3.03.
The historical data trend for Ortho Clinical Diagnostics Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortho Clinical Diagnostics Holdings Annual Data | |||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||
Enterprise Value | - | - | - | - | 7,027.69 |
Ortho Clinical Diagnostics Holdings Quarterly Data | ||||||||||||
Dec17 | Dec18 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Enterprise Value | Get a 7-Day Free Trial | 6,771.20 | 7,134.86 | 6,401.33 | 7,027.69 | 6,407.94 |
For the Diagnostics & Research subindustry, Ortho Clinical Diagnostics Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Ortho Clinical Diagnostics Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Ortho Clinical Diagnostics Holdings's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Ortho Clinical Diagnostics Holdings's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
Enterprise Value (A: Dec. 2021 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 5073.79356 | + | 0.1 | + | 2186.7 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 76.8 | + | 0 | - | 309.7 |
= | 7,028 |
Ortho Clinical Diagnostics Holdings's Enterprise Value for the quarter that ended in Mar. 2022 is calculated as
Enterprise Value (Q: Mar. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 4436.1351 | + | 0.1 | + | 2177.1 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 75.7 | + | 0 | - | 281.1 |
= | 6,408 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ortho Clinical Diagnostics Holdings (NAS:OCDX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Ortho Clinical Diagnostics Holdings's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 6163.066 | / | 130.3 | |
= | 47.30 |
Ortho Clinical Diagnostics Holdings's current Enterprise Value is $6,163 Mil.
Ortho Clinical Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $130 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Ortho Clinical Diagnostics Holdings's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 6163.066 | / | 455.1 | |
= | 13.54 |
Ortho Clinical Diagnostics Holdings's current Enterprise Value is $6,163 Mil.
Ortho Clinical Diagnostics Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $455 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Ortho Clinical Diagnostics Holdings's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 6163.066 | / | 2036.1 | |
= | 3.03 |
Ortho Clinical Diagnostics Holdings's current Enterprise Value is $6,163 Mil.
Ortho Clinical Diagnostics Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,036 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ortho Clinical Diagnostics Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Clifton Yates | director | C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869 |
Chockalingam Palaniappan | officer: Chief Innovation Officer | C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869 |
Christopher M Smith | director, officer: Chairman and CEO | 125 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Michael S. Iskra | officer: Executive Vice President | C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS, 1001 ROUTE 202, RARITAN NJ 08869 |
Joseph M Busky | officer: Chief Financial Officer | 1717 DEERFIELD ROAD, DEERFIELD IL 60015 |
Michael A. Schlesinger | officer: EVP, GC and Secretary | C/O ORTHO CLINICAL DIAGNOSTICS HOLDINGS 1001 ROUTE 202 RARITAN NJ 08869 |
Carlyle Partners Vi Cayman Holdings, L.p. | 10 percent owner | C/O WALKERS CORPORATE LIMITED, CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD., GEORGE TOWN, GRAND CAYMAN E9 KY1-9008 |
Tc Group Vi Cayman, L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Tc Group Vi Cayman, L.p. | 10 percent owner | C/O WALKERS CORPORATE LIMITED, CAYMAN CORPORATE CENTRE, 27 HOSPITAL RD., GEORGE TOWN, GRAND CAYMAN E9 KY1-9008 |
Cg Subsidiary Holdings L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Tc Group Cayman Investment Holdings Sub L.p. | 10 percent owner | C/O WALKER CORPORATE SERVICES LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9001 |
Carlyle Holdings Ii L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Holdings Ii Gp L.l.c. | 10 percent owner | C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505 |
Carlyle Group Inc. | 10 percent owner | C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
Tc Group Cayman Investment Holdings, L.p. | 10 percent owner | C/O WALKERS CORPORATE SERVICES LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9001 |
From GuruFocus
By PRNewswire PRNewswire • 09-27-2021
By PRNewswire PRNewswire • 09-27-2021
By GuruFocusNews GuruFocusNews • 01-04-2022
By GuruFocusNews GuruFocusNews • 04-20-2022
By GuruFocusNews GuruFocusNews • 12-27-2021
By PRNewswire PRNewswire • 01-05-2022
By PRNewswire PRNewswire • 12-24-2021
By GuruFocusNews GuruFocusNews • 12-25-2021
By Marketwired Marketwired • 09-14-2021
By GuruFocusNews GuruFocusNews • 12-23-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.